Objective: To evaluate the effect of transrectal ultrasound-guided prostate biopsy on lower urinary system symptoms. Materials and Methods: The study included 123 patients who underwent ultrasound-guided prostate biopsy between March 2013 and December 2013. Before and at 2, 4, and 8 weeks after the procedure, the patients completed the International Prostate Symptom Score (IPSS) questionnaire. Storage symptoms (questions 2, 4, 7) and voiding/postvoiding symptoms (questions 1, 3, 5, 6) were separately evaluated. The patients with cancer diagnosis were excluded after the week 4. The cancer-free patients were divided into subgroups based on education level and complication status and followed for 8 weeks to assess changes in IPSS and quality of life. Results: IPSS increased significantly at week 2 follow-up of both the cancerous and cancer-free patients (p=0.041 and p<0.01); however, there was no statistically significant difference between the pre-biopsy scores and week 4 scores (p=0.07 and p=0.09). Voiding/postvoiding symptoms also increased significantly at week 2 for both groups (p=0.04 and p<0.01, respectively). IPSS was significantly higher in all subgroups of cancer-free patients at week 2, in correlation with voiding/postvoiding symptoms. In patients with low education level, there was a significant decrease in IPSS at 4 and 8 weeks compared to pre-biopsy (p=0.031 and p=0.035, respectively). IPSS changes were not associated with prostate volume. Quality of life was significantly reduced in the early period (p<0.01). Conclusion: Lower urinary system symptoms are affected negatively in the early post-biopsy period in correlation with the increase of voiding/postvoiding symptoms. The time required for remission is 15-30 days. The procedure may decrease symptoms in patients with low education level due to the placebo effect.